The prognostic value of HCG, PAPP-A, oestradiol-17 beta and progesterone in early human pregnancy. 1986

J L Yovich, and D L Willcox, and J G Grudzinskas, and A E Bolton

Four serum parameters were assayed weekly from the 4th to the 12th week of pregnancy and finally at 16 weeks, to assess their relative prognostic values for predicting pregnancy outcome. Of 85 pregnancies generated following treatment for infertility, 16 cases had blighted ova and subsequently aborted at a mean age of 9.9 +/- 0.5 weeks. Serum HCG concentrations differentiated (p less than 0.005) between ongoing pregnancies and blighted ova as early as the 4th week which was often several weeks in advance of clinical abortion. PAPP-A, oestradiol-17 beta and progesterone did not differentiate between the 2 groups until 7 weeks (p less than 0.005, p less than 0.001 and p less than 0.001 respectively). PAPP-A measurements detected ongoing pregnancies at week 4 (16.5 +/- 5 micrograms/l) but HCG remains the more sensitive diagnostic test. The lower limits of oestradiol-17 beta and progesterone for ongoing pregnancies were 670 pmol/l and 37 nmol/l respectively. The circulating concentrations of all 4 serum markers were unaffected by administration of medroxyprogesterone acetate from 6 to 16 weeks in both ongoing and aborting pregnancies.

UI MeSH Term Description Entries
D007247 Infertility, Female Diminished or absent ability of a female to achieve conception. Sterility, Female,Sterility, Postpartum,Sub-Fertility, Female,Subfertility, Female,Female Infertility,Female Sterility,Female Sub-Fertility,Female Subfertility,Postpartum Sterility,Sub Fertility, Female
D008525 Medroxyprogesterone A synthetic progestational hormone used in veterinary practice as an estrus regulator. (6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione,Methylhydroxyprogesterone,Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-,17 alpha-Hydroxy-6 alpha-Methylprogesterone,Adgyn Medro,17 alpha Hydroxy 6 alpha Methylprogesterone
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011257 Pregnancy Proteins Proteins produced by organs of the mother or the PLACENTA during PREGNANCY. These proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.) Placental Proteins,Proteins, Placental,Proteins, Pregnancy
D011266 Pregnancy-Associated Plasma Protein-A A product of the PLACENTA, and DECIDUA, secreted into the maternal circulation during PREGNANCY. It has been identified as an IGF binding protein (IGFBP)-4 protease that proteolyzes IGFBP-4 and thus increases IGF bioavailability. It is found also in human FIBROBLASTS, ovarian FOLLICULAR FLUID, and GRANULOSA CELLS. The enzyme is a heterotetramer of about 500-kDa. PAPP-A,IGFBP-4 Metalloproteinase,IGFBP-4 Protease,IGFBP-4-Specific Proteinase,Insulin-Like Growth Factor-Dependent IGF Binding Protein-4 Protease,Insulin-Like-Growth Factor Binding Protein-4 Protease,PAPP-alpha,Pregnancy Associated alpha Plasma Protein,Pregnancy-Associated alpha-Plasma Protein,IGFBP 4 Metalloproteinase,IGFBP 4 Protease,Insulin Like Growth Factor Binding Protein 4 Protease,Insulin Like Growth Factor Dependent IGF Binding Protein 4 Protease,Metalloproteinase, IGFBP-4,PAPP alpha,Pregnancy Associated Plasma Protein A,Protease, IGFBP-4
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot

Related Publications

J L Yovich, and D L Willcox, and J G Grudzinskas, and A E Bolton
July 1978, Clinical endocrinology,
J L Yovich, and D L Willcox, and J G Grudzinskas, and A E Bolton
August 1994, American journal of obstetrics and gynecology,
J L Yovich, and D L Willcox, and J G Grudzinskas, and A E Bolton
July 1979, Prostaglandins,
J L Yovich, and D L Willcox, and J G Grudzinskas, and A E Bolton
October 1981, British journal of obstetrics and gynaecology,
J L Yovich, and D L Willcox, and J G Grudzinskas, and A E Bolton
December 1979, Clinical endocrinology,
J L Yovich, and D L Willcox, and J G Grudzinskas, and A E Bolton
May 1992, Human reproduction (Oxford, England),
J L Yovich, and D L Willcox, and J G Grudzinskas, and A E Bolton
January 1981, Clinical and experimental obstetrics & gynecology,
J L Yovich, and D L Willcox, and J G Grudzinskas, and A E Bolton
April 1980, Zentralblatt fur Veterinarmedizin. Reihe A,
J L Yovich, and D L Willcox, and J G Grudzinskas, and A E Bolton
July 1979, Acta psychiatrica Scandinavica,
Copied contents to your clipboard!